Navigation Links
Angioslide Announces the European Launch of New 300 mm Long Device Allowing Treatment of Entire Superficial Femoral Artery(SFA) with One Device
Date:9/8/2011

CAESAREA, Israel, September 8, 2011 /PRNewswire/ --

Angioslide Ltd. announces the first procedures with its new 5x300mm PROTEUS device for treating the Superficial Femoral Artery (SFA).  PROTEUS technology combines a Percutaneous Transluminal Angioplasty (PTA) balloon and embolic capture of particles in one device. The new 5x300 mm size joins Angioslide's current dedicated product line solutions for the lower limbs.

Initial treatments using the new PROTEUS device were conducted in leading world centers, Parkkrankenhaus Leipzig and Herzzentrum Bad Krozingen, located in Germany. The PROTEUS 5X300 mm makes it possible to treat lesions up to 300 mm with one device, while providing an immediate solution for embolic capture.

"Angioslide's breakthrough technology, now available also in 300 mm length as well, is a unique solution for lesions with high level of embolic material, including Chronic Total Occlusions (CTO), in stent-restenosis, thrombus containing lesions and post atherectomy PTA," said Prof. Thomas Zeller, Head of the Angiology Department, Heart Center Bad-Krozingen.

Prof.  Dierk Scheinert, Head of the Department of Angiology, Park-Krankenhaus Leipzig, adds, "We have been using the PROTEUS product line as part of our daily practice for a few years, and are working closely with the Angioslide team. I welcome the release of the 5X300 mm.  We can now use one device to treat patients with SFA diseases, which facilitates the procedural flow and makes the intervention cost-effective."

With the increase in life expectancy, diabetes prevalence, and number of high-risk patients, together  with the shift toward an "endovascular-first" approach as a preferred procedure over surgical revascularization, there is a growing need for expanding the current interventional "tool box" to accommodate procedures designed specifically to treat long and diffuse lesions in a quick and effective manner.

"We are committed to introducing new products to the market continuously, addressing the growing range of endovascular solutions," said Lihu Avitov, Angioslide CEO. "With patients' needs in mind, the 5X300 mm device is the first in a series of long balloons, adding to our current offering of 20-100 mm devices. The PROTEUS product family provides additional confidence to clinicians treating their endovascular patients."

The PROTEUS 5X300 mm is currently released for the European market only, and is undergoing an evaluation regulatory process with the FDA.

About Angioslide

Founded in 2005, Angioslide is a privately held medical device company that developed a unique Embolic Capture Angioplasty solution, PROTEUS™, which provides a combination of PTA balloon and embolic capture. The PROTEUS™ device addresses an unmet need for an easy-to-use, efficient and cost-effective embolic particle capture solution for the peripheral vascular disease market. It is the first device of its kind to receive FDA clearance for use in lower limbs. The device has also received European CE Mark approval for lower limb use and is being marketed in selected regions in Europe. Angioslide headquarters are located in Caesarea, Israel, with regional offices in Europe and the US. For more information visit our website at http://www.angioslide.com

Contact:
Shira Doron
Marketing Director
Mobile: +972-54-9011134
Email: shirad@angioslide.com



'/>"/>
SOURCE Angioslide Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... July 20, 2017  Prime Therapeutics LLC (Prime) released this ... M.D., following today,s Institute for Clinical and Economic Review,s (ICER) ... the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. ... roundtable at the meeting. ... cost benefit to the use of abuse-deterrent formulations (ADF) in ...
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
(Date:7/12/2017)... -- Eli Lilly and Company (NYSE: LLY ) has ... pending patent litigation in the U.S. District Court for the ... Cialis ® (tadalafil) unit dose patent. This patent was ... of the agreement, Cialis exclusivity is now expected to end ... unit dose patent for Cialis is valid and infringed by ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The ... consultations to communities in the greater Denver region, is announcing a charity drive ... a very rare kind of epilepsy. , Until a few months ago, Dominik ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Karen ... services to communities in the greater Birmingham area, is joining the Chris Hammond ... young people in the region. , The Chris Hammond Youth Foundation maintains athletic ...
(Date:7/21/2017)... PHILADELPHIA (PRWEB) , ... July 21, 2017 , ... ... ARTZ Philadelphia and Theater of Witness , was awarded a $300,000 ... growing humanities program which fosters empathy, comfort with ambiguity and the recognition of ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has filed a ... its ginger ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” ... plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... medical students improve their chances of acceptance to a residency in a United ... have earned degrees outside the U.S. , According to data released by the ...
Breaking Medicine News(10 mins):